Carterra, a provider of label-free antibody screening and characterisation, has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer. Under the agreement the agreement, PerkinElmer will market, sell, and service the company’s LSA high-throughput surface plasmon resonance platform and software, which is used designed to accelerate the discovery of therapeutic antibodies.
This move will help the company meet growing customer demand, it says, by leveraging PerkinElmer’s channel infrastructure in the region. It will also add additional tools to the distributor’s portfolio of science and biologics discovery offerings.
The agreement builds on an equity investment PerkinElmer made in the company last December, which has since led to several collaborations between the companies involving assay development and software integration projects.
Alan Fletcher, Senior VP, Life Science, PerkinElmer, said: “We are delighted to add the distribution of Carterra’s highly innovative LSA technology to help our Asia-Pacific and Oceania customers further streamline and advance their biologic and biotherapeutic discovery and development work.”
“Carterra recognised early on that Asia-Pacific and Oceania would be important markets for our game changing biologics discovery products and we are at the point where we need additional reach and channel power to help us take our customer delivery there to the next level, ” said Tim Germann, CCO at Carterra. “We are excited to collaborate with PerkinElmer to add that extra horsepower in sales, marketing and service as well as benefit from their deep life science expertise across drug development workflows.”
